BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19711075)

  • 1. Lytic activity against primary AML cells is stimulated in vitro by an autologous whole cell vaccine expressing IL-2 and CD80.
    Hardwick N; Chan L; Ingram W; Mufti G; Farzaneh F
    Cancer Immunol Immunother; 2010 Mar; 59(3):379-88. PubMed ID: 19711075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human CD80/IL2 lentivirus transduced acute myeloid leukaemia cells enhance cytolytic activity in vitro in spite of an increase in regulatory CD4+ T cells in a subset of cultures.
    Ingram W; Kordasti S; Chan L; Barber LD; Tye GJ; Hardwick N; Mufti GJ; Farzaneh F
    Cancer Immunol Immunother; 2009 Oct; 58(10):1679-90. PubMed ID: 19283381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human CD80/IL2 lentivirus-transduced acute myeloid leukaemia (AML) cells promote natural killer (NK) cell activation and cytolytic activity: implications for a phase I clinical study.
    Ingram W; Chan L; Guven H; Darling D; Kordasti S; Hardwick N; Barber L; Mufti GJ; Farzaneh F
    Br J Haematol; 2009 Jun; 145(6):749-60. PubMed ID: 19388935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-2/B7.1 (CD80) fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: a strategy to generate whole cell vaccines for AML.
    Chan L; Hardwick N; Darling D; Galea-Lauri J; Gäken J; Devereux S; Kemeny M; Mufti G; Farzaneh F
    Mol Ther; 2005 Jan; 11(1):120-31. PubMed ID: 15585413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-15/IL-15Rα/CD80-expressing AML cell vaccines eradicate minimal residual disease in leukemic mice.
    Shi Y; Dincheva-Vogel L; Ayemoba CE; Fung JP; Bergamaschi C; Pavlakis GN; Farzaneh F; Gaensler KML
    Blood Adv; 2018 Nov; 2(22):3177-3192. PubMed ID: 30482760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting of a B7-1 (CD80) immunoglobulin G fusion protein to acute myeloid leukemia blasts increases their costimulatory activity for autologous remission T cells.
    Notter M; Willinger T; Erben U; Thiel E
    Blood; 2001 May; 97(10):3138-45. PubMed ID: 11342441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD80-Transfected acute myeloid leukemia cells induce primary allogeneic T-cell responses directed at patient specific minor histocompatibility antigens and leukemia-associated antigens.
    Mutis T; Schrama E; Melief CJ; Goulmy E
    Blood; 1998 Sep; 92(5):1677-84. PubMed ID: 9716596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition.
    Costello RT; Mallet F; Sainty D; Maraninchi D; Gastaut JA; Olive D
    Eur J Immunol; 1998 Jan; 28(1):90-103. PubMed ID: 9485189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD80 (B7-1) expression on human acute myeloid leukaemic cells cultured with GM-CSF, IL-3 and IL-6.
    Hicks C; Keoshkerian E; Gaudry L; Lindeman R
    Cancer Immunol Immunother; 2001 Jun; 50(4):173-80. PubMed ID: 11459169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lactate dehydrogenase-release assay: a reliable, nonradioactive technique for analysis of cytotoxic lymphocyte-mediated lytic activity against blasts from acute myelocytic leukemia.
    Weidmann E; Brieger J; Jahn B; Hoelzer D; Bergmann L; Mitrou PS
    Ann Hematol; 1995 Mar; 70(3):153-8. PubMed ID: 7718644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lentiviral vectors for efficient delivery of CD80 and granulocyte-macrophage- colony-stimulating factor in human acute lymphoblastic leukemia and acute myeloid leukemia cells to induce antileukemic immune responses.
    Stripecke R; Cardoso AA; Pepper KA; Skelton DC; Yu XJ; Mascarenhas L; Weinberg KI; Nadler LM; Kohn DB
    Blood; 2000 Aug; 96(4):1317-26. PubMed ID: 10942373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines.
    Dunussi-Joannopoulos K; Dranoff G; Weinstein HJ; Ferrara JL; Bierer BE; Croop JM
    Blood; 1998 Jan; 91(1):222-30. PubMed ID: 9414288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro co-stimulation with anti-CD28 synergizes with IL-12 in the generation of T cell immune responses to leukaemic cells; a strategy for ex-vivo generation of CTL for immunotherapy.
    Orleans-Lindsay JK; Deru A; Craig JI; Prentice HG; Lowdell MW
    Clin Exp Immunol; 2003 Sep; 133(3):467-75. PubMed ID: 12930376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of cytokines and CD80 for enhancement of immunogenicity of cervical cancer cells.
    Kaufmann AM; Gissmann L; Simms P; Schreckenberger C; Qiao L
    Immunobiology; 2000 Nov; 202(4):339-52. PubMed ID: 11131151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone marrow-derived T-cell clones obtained from untreated acute myelocytic leukemia exhibit blast directed autologous cytotoxicity.
    Jahn B; Bergmann L; Weidmann E; Brieger J; Fenchel K; Schwulera U; Hoelzer D; Mitrou PS
    Leuk Res; 1995 Feb; 19(2):73-82. PubMed ID: 7869744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum-free generation and quantification of functionally active Leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes.
    Kufner S; Fleischer RP; Kroell T; Schmid C; Zitzelsberger H; Salih H; de Valle F; Treder W; Schmetzer HM
    Cancer Immunol Immunother; 2005 Oct; 54(10):953-70. PubMed ID: 15789235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restimulation of tumour-specific immunity in a patient with AML following injection with B7-1 positive autologous blasts.
    Hicks C; Cheung C; Lindeman R
    Leuk Res; 2003 Nov; 27(11):1051-61. PubMed ID: 12859998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Augmentation of autologous T cell reactivity with acute myeloid leukemia (AML) blasts by Toll-like receptor (TLR) agonists.
    Zhong R; Li H; Messer K; Lane TA; Zhou J; Ball ED
    Cancer Immunol Immunother; 2015 Jun; 64(6):737-44. PubMed ID: 25795133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of gamma-irradiation on acute myelogenous leukemia blasts: in vitro studies of proliferation, constitutive cytokine secretion, and accessory cell function during T cell activation.
    Bruserud O; Ulvestad E
    J Hematother Stem Cell Res; 1999 Aug; 8(4):431-41. PubMed ID: 10634181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
    Pituch-Noworolska A
    Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.